The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Virginie Westeel
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Pfizer; Lilly; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb; Roche; Sanofi
 
Ian Anderson
No Relationships to Disclose
 
Laurent Greillier
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Novocure; Pfizer; Regeneron; Roche; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Novocure; Roche; Takeda
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; MSD; Pfizer; Roche
 
Florian Guisier
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda; Viatris
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi
Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD; Takeda
 
Olivier Bylicki
No Relationships to Disclose
 
Firas Badin
Speakers' Bureau - Bristol-Myers Squibb/Pfizer; GE Healthcare; Jazz Pharmaceuticals; Lilly; Merck; Merck Serono; Regeneron
 
Gaelle Rousseau-Bussac
No Relationships to Disclose
 
Clotilde Deldycke
No Relationships to Disclose
 
Frank Griesinger
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Jansen Cilag; Johnson & Johnson/Janssen; MSD; Novartis; Pfizer; Regeneron; Roche/Genentech; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche/Genentech; Takeda; Takeda; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Roche (Inst); Takeda (Inst)
 
Adam Bograd
No Relationships to Disclose
 
Wangjian Zhong
No Relationships to Disclose
 
Matthew Gubens
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Atreca; Bristol Myers Squibb; Cardinal Health; Gilead Sciences; Guardant Health; InVitae; Johnson & Johnson/Janssen; Merus; Summit Therapeutics
Research Funding - Amgen (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Trizell (Inst)
 
John Crowley
No Relationships to Disclose
 
Heiko von der Leyen
No Relationships to Disclose
 
Gavitt Woodard
Consulting or Advisory Role - AstraZeneca
 
Johannes Kratz
Stock and Other Ownership Interests - OncoCyte
Honoraria - Curio Science; DAVA Oncology
Consulting or Advisory Role - Intuitive Surgical; Razor Genomics
Patents, Royalties, Other Intellectual Property - UCSF patent for prognostic assay for early-stage lung cancer
Travel, Accommodations, Expenses - Intuitive Surgical
 
David Jablons
Patents, Royalties, Other Intellectual Property - Multiple patents owned by UCSF
 
Michael Mann
Leadership - Razor Genomics
Stock and Other Ownership Interests - RasCal
Patents, Royalties, Other Intellectual Property - Univ. Calfornia San Francisco